Table 3.

Subtypes of cancer in patients undergoing lung cancer screening

	Overall Cohort	SPLC Patients
Cancer	No. of Patients (%)	No. of Patients (%)	Rate of SPLC within cancer type
Breast	205 (37.8%)	11 (30.5%)	5.4%
Head and Neck	105 (19.3%)	7 (19%)	6.7%
Lung	87 (16.0%)	7 (19%)	8.0%
Prostate	66 (12.2%)	3 (8%)	4.5%
Renal cell carcinoma	41 (7.6%)	1 (3%)	2.4%
Thyroid	27 (5.0%)	2 (5.5%)	7.4%
Bladder	22 (4.1%)	1 (3%)	4.5%
Colorectal	22 (4.1%)	2 (5.5%)	9.0%
Melanoma	18 (3.3%)	3 (8%)	16.7%
Lymphoma	11 (1.8%)	1 (3%)	9.1%
Esophagus	6 (1.1%)	0 (0%)	0%
Ovarian	4 (0.7%)	0 (0%)	0%
Gastric	3 (0.6%)	0 (0%)	0%
Cervix	3 (0.6%)	0 (0%)	0%
Chronic Lymphocytic Leukemia	2 (0.4%)	0 (0%)	0%
Myeloma	1 (0.2%)	0 (0%)	0%

Percentages are ≥100% as 112 patients had more than 1 cancer diagnosis.

SPLC = second primary lung cancer